A Study Explore JS001+JS002 in Patients With Advanced Cancer
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Recombinant Humanized Anti-PCSK9 Monoclonal Antibody (JS002) Combined With Toripalimab in Patients With Advanced Cancer
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Terminated
The regimen of JS002 75\~300mg Q3W has been completed, and the combination therapy is well tolerated and safe. However, considering that the efficacy did not reach the preset, it is recommended to terminate the trial in advance.
Other terminated trials from Shanghai Junshi Bioscience Co., Ltd.
- Advanced Pancreatic Cancer · Phase PHASE1 · Jan 2025
- Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer · Phase PHASE1 · Jan 2024
- Hepatocellular Carcinoma · Phase PHASE1/PHASE2 · Aug 2023
- Advanced Solid Tumors · Phase PHASE1 · Jun 2023
- Advanced or Metastatic Solid Tumors · Phase PHASE1 · Sep 2022
More terminations from Shanghai Junshi Bioscience Co., Ltd.
This PHASE1 trial investigates Advanced Cancer and is currently terminated or withdrawn. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Feb 2022 — Apr 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Junshi Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .